Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on June 5, 2008

Stroke. 2008
Published online before print June 5, 2008, doi: 10.1161/STROKEAHA.107.505354
A more recent version of this article appeared on August 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/8/2280    most recent
STROKEAHA.107.505354v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montaner, J.
Right arrow Articles by Alvarez-Sabín, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montaner, J.
Right arrow Articles by Alvarez-Sabín, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Other diagnostic testing
Right arrow Acute Stroke Syndromes
Right arrow Embolic stroke
Right arrow Transient Ischemic Attacks

Submitted on September 24, 2007
Revised on January 2, 2008
Accepted on January 16, 2008

Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers

Joan Montaner MD, PhD*; Mila Perea-Gainza MD; Pilar Delgado MD, PhD; Marc Ribó MD, PhD; Pilar Chacón MD, PhD; Anna Rosell PhD; Manolo Quintana; Mauricio E. Palacios MD; Carlos A. Molina MD, PhD; and José Alvarez-Sabín MD, PhD

From the Neurovascular Research Laboratory, Neurovascular Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain.

* To whom correspondence should be addressed. E-mail: 31862jmv{at}comb.es.

Background and Purpose—Because there is no biologic marker offering precise information about stroke etiology, many patients receive a diagnosis of undetermined stroke even after all available diagnostic tests are done, precluding correct treatment.

Methods—To examine the diagnostic value of a panel of biochemical markers to differentiate stroke etiologies, consecutive acute stroke patients were prospectively evaluated. Brain computed tomography, ultrasonography, cardiac evaluations, and other tests were done to identify an etiologic diagnosis according to TOAST classification. Blood samples were drawn on Emergency Department arrival (<24 hours) to test selected biomarkers: C-reactive protein, D-dimer, soluble receptor for advanced glycation end products, matrix metalloproteinase-9, S-100b, brain natriuretic peptide (BNP), neurotrophin-3, caspase-3, chimerin, and secretagogin (assayed by ELISA).

Results—Of 707 ischemic stroke patients included, 36.6% were cardioembolic, 21.4% atherothrombotic, 18.1% lacunar, and 23.9% of undetermined origin. High levels of BNP, soluble receptor for advanced glycation end products, and D-dimer (P<0.0001) were observed in patients with cardioembolic stroke. Independent predictors (odds ratios with CIs are given) of cardioembolic stroke were as follows: atrial fibrillation 15.3 (8.4–27.7, P<0.001); other embolic cardiopathies 14.7 (4.7–46, P<0.001); total anterior circulation infarction 4 (2.3–6.8, P<0.001); BNP >76 pg/mL 2.3 (1.4–3.7, P=0.001); and D-dimer >0.96 µg/mL 2.2 (1.4–3.7, P=0.001). Even among patients with transient symptoms (n=155), a high BNP level identified cardioembolic etiology (6.7, 2.4–18.9; P<0.001). A model combining clinical and biochemical data had a sensitivity of 66.5% and a specificity of 91.3% for predicting cardioembolism.

Conclusions—Using a combination of biomarkers may be a feasible strategy to improve the diagnosis of cardioembolic stroke in the acute phase, thus rapidly guiding other diagnostic tests and accelerating the start of optimal secondary prevention.


Key words: atherosclerosis • cerebral ischemia • natriuretic peptides • embolism • D-dimer • stroke




This article has been cited by other articles:


Home page
Clin. Chem.Home page
G. T. Jones, M. Deng, G. D. Hammond-Tooke, S. P. A. McCormick, and A. M. van Rij
Increased Plasma Lipoprotein(a) Found in Large-Artery Atherosclerotic, but Not Small-Artery Occlusive, Stroke
Clin. Chem., October 1, 2009; 55(10): 1888 - 1890.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases
Rheumatology, October 1, 2009; 48(10): 1190 - 1196.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. Whiteley, W. L. Chong, A. Sengupta, and P. Sandercock
Blood Markers for the Prognosis of Ischemic Stroke: A Systematic Review
Stroke, May 1, 2009; 40(5): e380 - e389.
[Abstract] [Full Text] [PDF]